false
OasisLMS
Catalog
Pulmonary Self-Study Resources
What is Biomarker Testing for Advanced Lung Cancer ...
What is Biomarker Testing for Advanced Lung Cancer and Why is it Important? - Video
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this webinar, Dr. Bruce Johnson discusses the importance of biomarker testing for advanced lung cancer. He highlights different mutations, such as EGFR, ALK, ROS1, BRAF, and PD-L1, for which targeted therapies are available. Dr. Johnson emphasizes the significant impact of biomarker testing on patient outcomes, citing examples of patients who have experienced prolonged responses and improved survival with targeted therapies. He also discusses the testing rates for these biomarkers and the need for broader molecular testing to identify emerging biomarkers. Dr. Johnson emphasizes the importance of testing for both smokers and non-smokers as these genomic changes can occur in anyone. He also highlights the lower toxicity profiles of targeted therapies compared to traditional chemotherapy, making them suitable for a broader range of patients. Dr. Johnson concludes by discussing the role of biomarker testing in early stage lung cancer and the expansion of targeted therapies in this setting. Overall, Dr. Johnson emphasizes the importance of biomarker testing in personalizing treatment approaches for patients with advanced lung cancer.
Meta Tag
Asset Type
Video
Curriculum Category
Neoplasia
Curriculum Subcategory
Lung cancer
Keywords
biomarker testing
advanced lung cancer
mutations
targeted therapies
patient outcomes
molecular testing
emerging biomarkers
genomic changes
toxicity profiles
×
Please select your language
1
English